Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study

Yukari Okubo,Tadashi Terui,Satomi Kobayashi,Shigetoshi Sano,Akimichi Morita,Shinichi Imafuku,Yayoi Tada,Masatoshi Abe,Masafumi Yaguchi,Takeshi Kimura,Junichiro Shimauchi,Wendy Zhang,Hamid Amouzadeh,Masamoto Murakami

DOI: https://doi.org/10.1007/s13555-024-01195-z

2024-06-20

Dermatology and Therapy

Abstract:Palmoplantar pustulosis (PPP) is a pruritic, painful, chronic dermatitis that greatly impacts functioning and quality of life and can be difficult to treat. Approved treatment options for PPP are limited, and many patients do not fully respond to current treatments.

dermatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the exploratory efficacy of apremilast in treating Japanese patients with palmoplantar pustulosis (PPP). Specifically, the study aims to:

1. **Evaluate the efficacy of apremilast**: By comparing the efficacy of apremilast and placebo within 16 weeks, especially in reducing the overall severity of PPP.
2. **Maintenance of long - term efficacy**: Evaluate whether the efficacy of apremilast can be sustained or further improved within 32 weeks.
3. **Efficacy in different subgroups of patients**: Analyze the efficacy of apremilast in different subgroups of baseline demographics and disease characteristics, especially the response rate of PPPASI - 50 (that is, at least 50% improvement in PPPASI score).

### Research background
Palmoplantar pustulosis (PPP) is a pruritic, painful chronic skin disease, which seriously affects the function and quality of life of patients and is difficult to treat. Currently, the approved treatment options are limited, and many patients do not respond well to the existing treatment methods. Apremilast is an oral phosphodiesterase 4 inhibitor, which has shown efficacy in diseases such as psoriasis, but its efficacy in PPP still needs further verification.

### Methods
- **Study design**: This is a multi - center, randomized, double - blind, placebo - controlled parallel - group phase II trial.
- **Subjects**: Japanese patients with moderate to severe PPP who did not respond well to local treatment were included.
- **Grouping**: Patients were randomly assigned in a 1:1 ratio to the apremilast 30 mg twice daily group or the placebo group for 16 weeks. After that, all patients received apremilast treatment until the 32nd week.
- **Evaluation indicators**: The primary endpoint was the response rate of PPPASI - 50 at the 16th week, and the secondary endpoints included the changes in the total PPPASI and modified PPPASI scores and their sub - scores, as well as the changes in the PPSI total score.

### Results
- **Short - term efficacy**: At the 16th week, the improvement in the total PPPASI score and sub - scores in the apremilast group was significantly better than that in the placebo group.
- **Long - term efficacy**: At the 32nd week, the improvement in the total PPPASI score and sub - scores in the apremilast group was maintained and even further improved.
- **Subgroup analysis**: Apremilast showed better efficacy than placebo in most subgroups of baseline demographics and disease characteristics, especially in the response rate of PPPASI - 50.

### Conclusion
Apremilast shows significant efficacy in treating patients with moderate to severe PPP, and this efficacy is maintained or further improved within 32 weeks. Apremilast has an improvement effect on all symptoms of PPP (such as erythema, pustules, blisters and desquamation), and the performance is consistent in most patient subgroups. These results suggest that apremilast may be an effective option for treating PPP.